Drug Research

Resistance to historically effective antimalarial drugs has contributed to the resurgence of malaria across sub-Saharan Africa in the past decade. The recent discovery of parasitic resistance to Artemisinin monotherapies underscores the urgent need for new and more effective antimalarial treatments.

Medicines for Malaria Venture (MMV) is a non-profit organization created to discover, develop and deliver new antimalarial drugs through effective public-private partnerships. MMV does this by providing drug companies with supplmental funding, technical expertise and logistical support. It currently has over 20 new products in the pipeline.

For more information about Drug Research for malaria control, please visit MMV's website.

Must Read Malaria Keeps Killing Millions May 16, 2023 GlaxoSmithKline and Medicines For Malaria Venture announce new collaboration to investigate novel antimalarial compounds January 28, 2024 Newest Malaria Medicine May Be Losing Potency in Asia, WHO Says October 17, 2023 Certain Combination Therapy Found More Effective For Treating Malaria In African Children May 28, 2023 Scientists discover new compound that kills drug-resistant malaria February 12, 2024	AFM Articles Shelving malaria April 02, 2024 Malaria Drugs Shelf-Life Possibly Much Longer Than Expected February 26, 2024 Malaria Keeps Killing Millions May 16, 2023 Medicine tariffs: how they cost lives August 10, 2023 Remove Medical Tariffs February 27, 2024 » more...	News New hope for malaria July 06, 2023 Namibia: Unam Makes Breakthrough July 05, 2023 I did the maths. Vaccines make aid go furthest June 13, 2023 WHO global plan to contain drug-resistant malaria January 12, 2024 Award-winning malaria scientist warns of drug resistance October 25, 2023 » more...
Research Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children February 28, 2024 Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial September 09, 2023 Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments June 11, 2023 Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial November 17, 2023 The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum March 16, 2024 » more...	Press Releases DNDi Partners With Pharma, Biotech, Academia, Public Health Institutes & NGOs to Deliver Lifesaving Drugs June 24, 2023 Scientists discover new compound that kills drug-resistant malaria February 12, 2024 MissionMore than 4.3 million medicines tested thanks to calculation grids February 08, 2024 Novartis Institute for Tropical Diseases Inaugurates New Indonesian Research Initiative to Study Dengue fever, Tuberculosis and Malaria January 25, 2024	Events No Events found for this issue